475 related articles for article (PubMed ID: 20724890)
1. Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?
Luna CM; Bruno D; Aruj P
Crit Care Med; 2010 Sep; 38(9):1910-2. PubMed ID: 20724890
[No Abstract] [Full Text] [Related]
2. Variable daptomycin susceptibility in patients receiving intravenous vancomycin for meticillin-resistant Staphylococcus aureus infections.
Golden M; Shaib W; Havill N
Int J Antimicrob Agents; 2010 Mar; 35(3):306-8. PubMed ID: 20036108
[No Abstract] [Full Text] [Related]
3. Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment.
Tan CK; Lai CC; Lin SH; Hsueh PR
Crit Care Med; 2010 Aug; 38(8):1754; author reply 1754-5. PubMed ID: 20647809
[No Abstract] [Full Text] [Related]
4. Increasing levels of minimum inhibitory concentration vancomycin in methicillin resistant Staphylococcus aureus alarming bell for vancomycin abusers?
Veer P; Chande C; Chavan S; Wabale V; Chopdekar K; Bade J; Joshi A
Indian J Med Microbiol; 2010; 28(4):413-4. PubMed ID: 20966589
[No Abstract] [Full Text] [Related]
5. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK.
Lewis T; Chaudhry R; Nightingale P; Lambert P; Das I
Int J Infect Dis; 2011 Feb; 15(2):e131-5. PubMed ID: 21134776
[TBL] [Abstract][Full Text] [Related]
6. A refractory case of community-acquired pneumonia.
Schlaudecker JD
J Fam Pract; 2009 Nov; 58(11):573-5. PubMed ID: 19891934
[No Abstract] [Full Text] [Related]
7. Management of methicillin-resistant Staphylococcus aureus pneumonia.
Luna CM; Boyeras Navarro ID
Curr Opin Infect Dis; 2010 Apr; 23(2):178-84. PubMed ID: 20075728
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
9. [Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics].
Manfredi R; Nanetti A; Morelli S; Valentini R; Ferri M; Calza L; Chiodo F
Recenti Prog Med; 2003; 94(7-8):344. PubMed ID: 12868245
[No Abstract] [Full Text] [Related]
10. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
[No Abstract] [Full Text] [Related]
11. Atypical pneumonia linked to community-acquired staphylococcus aureus cross-transmission in the nursery.
Filleron A; Lotthé A; Jourdes E; Jeziorski E; Prodhomme O; Didelot MN; Parer S; Marchandin H; Cambonie G
Neonatology; 2013; 104(2):156-60. PubMed ID: 23886974
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
13. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Segarra-Newnham M; Church TJ
Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin minimum inhibitory concentrations (MICs) for meticillin-resistant Staphylococcus aureus (MRSA) in Hong Kong.
Ip M; Chau SS; Lui SL; Leung E; Ling T
Int J Antimicrob Agents; 2010 Oct; 36(4):386-7. PubMed ID: 20702065
[No Abstract] [Full Text] [Related]
15. [Use of vancomycin in the treatment of severe Staphylococcus aureus infection. Description of 3 cases].
Campelli A; Mantero E; Fabbri A; Nahum M; Ferraris R; Di Noto C
Minerva Med; 1984 Feb; 75(8):385-90. PubMed ID: 6709217
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
17. Nosocomial methicillin--resistant Staphylococcus aureus with reduced susceptibility to vancomycin.
Bhat G; Kamath S; Hussain A
Indian J Pathol Microbiol; 2006 Apr; 49(2):311-2. PubMed ID: 16933753
[No Abstract] [Full Text] [Related]
18. The role of vancomycin in the treatment paradigm.
Stevens DL
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
[TBL] [Abstract][Full Text] [Related]
19. Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics.
Moine P; Bédos JP
Chest; 2007 Sep; 132(3):1101, author reply 1102-3. PubMed ID: 17873216
[No Abstract] [Full Text] [Related]
20. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
Sakoulas G; Moellering RC; Eliopoulos GM
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S40-50. PubMed ID: 16323119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
